Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Standard

Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. / Wesolowski, Janusz; Alzogaray, Vanina; Reyelt, Jan; Unger, Mandy; Juarez, Karla; Urrutia, Mariela; Cauerhff, Ana; Danquah, Welbeck Owusu; Rissiek, Björn; Scheuplein, Felix; Schwarz, Nicole; Adriouch, Sahil; Boyer, Olivier; Seman, Michel; Licea, Alexei; Serreze, David; Goldbaum, Fernando; Haag, Friedrich; Koch Nolte, Friedrich.

in: MED MICROBIOL IMMUN, 2009.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Wesolowski, J, Alzogaray, V, Reyelt, J, Unger, M, Juarez, K, Urrutia, M, Cauerhff, A, Danquah, WO, Rissiek, B, Scheuplein, F, Schwarz, N, Adriouch, S, Boyer, O, Seman, M, Licea, A, Serreze, D, Goldbaum, F, Haag, F & Koch Nolte, F 2009, 'Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.', MED MICROBIOL IMMUN. <http://www.ncbi.nlm.nih.gov/pubmed/19529959?dopt=Citation>

APA

Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W. O., Rissiek, B., Scheuplein, F., Schwarz, N., Adriouch, S., Boyer, O., Seman, M., Licea, A., Serreze, D., Goldbaum, F., Haag, F., & Koch Nolte, F. (2009). Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. MED MICROBIOL IMMUN. http://www.ncbi.nlm.nih.gov/pubmed/19529959?dopt=Citation

Vancouver

Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. MED MICROBIOL IMMUN. 2009.

Bibtex

@article{e8776637ee684b80ad7dcc33925a4683,
title = "Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.",
abstract = "Antibodies are important tools for experimental research and medical applications. Most antibodies are composed of two heavy and two light chains. Both chains contribute to the antigen-binding site which is usually flat or concave. In addition to these conventional antibodies, llamas, other camelids, and sharks also produce antibodies composed only of heavy chains. The antigen-binding site of these unusual heavy chain antibodies (hcAbs) is formed only by a single domain, designated VHH in camelid hcAbs and VNAR in shark hcAbs. VHH and VNAR are easily produced as recombinant proteins, designated single domain antibodies (sdAbs) or nanobodies. The CDR3 region of these sdAbs possesses the extraordinary capacity to form long fingerlike extensions that can extend into cavities on antigens, e.g., the active site crevice of enzymes. Other advantageous features of nanobodies include their small size, high solubility, thermal stability, refolding capacity, and good tissue penetration in vivo. Here we review the results of several recent proof-of-principle studies that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.",
author = "Janusz Wesolowski and Vanina Alzogaray and Jan Reyelt and Mandy Unger and Karla Juarez and Mariela Urrutia and Ana Cauerhff and Danquah, {Welbeck Owusu} and Bj{\"o}rn Rissiek and Felix Scheuplein and Nicole Schwarz and Sahil Adriouch and Olivier Boyer and Michel Seman and Alexei Licea and David Serreze and Fernando Goldbaum and Friedrich Haag and {Koch Nolte}, Friedrich",
year = "2009",
language = "Deutsch",
journal = "MED MICROBIOL IMMUN",
issn = "0300-8584",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

AU - Wesolowski, Janusz

AU - Alzogaray, Vanina

AU - Reyelt, Jan

AU - Unger, Mandy

AU - Juarez, Karla

AU - Urrutia, Mariela

AU - Cauerhff, Ana

AU - Danquah, Welbeck Owusu

AU - Rissiek, Björn

AU - Scheuplein, Felix

AU - Schwarz, Nicole

AU - Adriouch, Sahil

AU - Boyer, Olivier

AU - Seman, Michel

AU - Licea, Alexei

AU - Serreze, David

AU - Goldbaum, Fernando

AU - Haag, Friedrich

AU - Koch Nolte, Friedrich

PY - 2009

Y1 - 2009

N2 - Antibodies are important tools for experimental research and medical applications. Most antibodies are composed of two heavy and two light chains. Both chains contribute to the antigen-binding site which is usually flat or concave. In addition to these conventional antibodies, llamas, other camelids, and sharks also produce antibodies composed only of heavy chains. The antigen-binding site of these unusual heavy chain antibodies (hcAbs) is formed only by a single domain, designated VHH in camelid hcAbs and VNAR in shark hcAbs. VHH and VNAR are easily produced as recombinant proteins, designated single domain antibodies (sdAbs) or nanobodies. The CDR3 region of these sdAbs possesses the extraordinary capacity to form long fingerlike extensions that can extend into cavities on antigens, e.g., the active site crevice of enzymes. Other advantageous features of nanobodies include their small size, high solubility, thermal stability, refolding capacity, and good tissue penetration in vivo. Here we review the results of several recent proof-of-principle studies that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.

AB - Antibodies are important tools for experimental research and medical applications. Most antibodies are composed of two heavy and two light chains. Both chains contribute to the antigen-binding site which is usually flat or concave. In addition to these conventional antibodies, llamas, other camelids, and sharks also produce antibodies composed only of heavy chains. The antigen-binding site of these unusual heavy chain antibodies (hcAbs) is formed only by a single domain, designated VHH in camelid hcAbs and VNAR in shark hcAbs. VHH and VNAR are easily produced as recombinant proteins, designated single domain antibodies (sdAbs) or nanobodies. The CDR3 region of these sdAbs possesses the extraordinary capacity to form long fingerlike extensions that can extend into cavities on antigens, e.g., the active site crevice of enzymes. Other advantageous features of nanobodies include their small size, high solubility, thermal stability, refolding capacity, and good tissue penetration in vivo. Here we review the results of several recent proof-of-principle studies that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.

M3 - SCORING: Zeitschriftenaufsatz

JO - MED MICROBIOL IMMUN

JF - MED MICROBIOL IMMUN

SN - 0300-8584

ER -